Citi analyst Joanne Wuensch raised the firm’s price target on Glaukos (GKOS) to $125 from $113 and keeps a Buy rating on the shares. The firm adjusted ratings and targets in the medical technology sector as part of its 2026 outlook. The group is “bouncing off its lows,” and there is further upside potential in 2026, the analyst tells investors in a research note. Citi believes the S&P Equipment and Supplies index “remains undervalued and underappreciated.” The firm expects a rebound next year due to company catalysts and sector rotation.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS:
- Glaukos price target raised to $125 from $117 at Needham
- Positive Outlook for Glaukos: Buy Rating Reinforced by Epioxa’s Market Potential and Increased Price Target
- Glaukos Highlights Innovation in November 2025 Presentation
- Beaten Down by 35%-Plus: Analysts Say These 2 Oversold Stocks Are Poised to Turn the Corner
- Glaukos Corp. Reports Record Sales and FDA Approval